Targeting these regulatory proteins (such as METTL3 inhibitors STM2457 and FTO inhibitors FB23-2) can reverse resistance and enhance the efficacy of immune checkpoint blockade, providing a new approach to overcoming tumor immune resistance (Li Y. et al., 2024). Here, FTO is linked to neoplasm.